Ionis Pharmaceuticals IONS Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current
Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's debt securities available for sale accumulated gross unrealized loss before tax current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's debt securities available for sale accumulated gross unrealized loss before tax current?
- Ionis Pharmaceuticals (IONS) reported debt securities available for sale accumulated gross unrealized loss before tax current of $594K in Q1 2026.
- How has Ionis Pharmaceuticals's debt securities available for sale accumulated gross unrealized loss before tax current changed year-over-year?
- Ionis Pharmaceuticals's debt securities available for sale accumulated gross unrealized loss before tax current increased by 8.2% year-over-year, from $549K to $594K.
- What is the long-term trend for Ionis Pharmaceuticals's debt securities available for sale accumulated gross unrealized loss before tax current?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's debt securities available for sale accumulated gross unrealized loss before tax current has grown at a -39.9% compound annual growth rate (CAGR), from $345K to $45K.
- What does debt securities available for sale accumulated gross unrealized loss before tax current mean?
- The total unrealized loss on current debt investments based on current market prices.
- How do you interpret debt securities available for sale accumulated gross unrealized loss before tax current?
- An increase signals potential market headwinds or rising interest rates affecting the value of the company's debt portfolio.
- How does debt securities available for sale accumulated gross unrealized loss before tax current compare across companies?
- Standard treasury risk metric across the pharmaceutical and biotech sectors.